Detalhe da pesquisa
1.
Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single-center, open-label TRITON study.
Am J Transplant
; 21(9): 3055-3065, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33565206
2.
Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: The Neptune study, a phase I single-center study.
Am J Transplant
; 20(10): 2905-2915, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32277568
3.
Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study.
J Transl Med
; 13: 344, 2015 Nov 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26537851
4.
Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients.
J Transl Med
; 12: 331, 2014 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-25491391
5.
Cell-free DNA measurement of three genomes after allogeneic MSC therapy in kidney transplant recipients indicates early cell death of infused MSC.
Front Immunol
; 14: 1240347, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38022634
6.
Low incidence of IgA isotype of HLA antibodies in alloantigen exposed individuals.
HLA
; 97(2): 101-111, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33227174
7.
Transplanting the Elderly: Mandatory Age- and Minimal Histocompatibility Matching.
Front Immunol
; 11: 359, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32226428